Stock Price & Analysis

Based on the provided data and current market conditions, here's a concise analysis of UTHR stock:

Technical Analysis

The stock is showing bearish momentum with RSI at 35.48, indicating oversold conditions. The stock is trading below both its 20-day (361.12) and 60-day (365.32) moving averages, suggesting a downward trend.

Recent Price Action The stock closed at $345.64 in regular trading hours and further declined to $344.23 in post-market trading, showing continued selling pressure. Current price levels are near the Fibonacci support level of $346.26.

Fundamental Catalysts

• FDA clearance for UKidney xenotransplantation clinical trial announced on February 3, 2025, with first transplant expected mid-2025
• Recent insider selling activity with COO selling 47.6% of holdings raises some concerns
• Strong institutional support with 293 institutions increasing positions versus 274 decreasing

Analyst Sentiment

UBS maintains a Strong Buy rating with a $475 price target, suggesting 29.57% upside potential. The consensus among analysts remains moderately bullish.

Recommendation SELL at current levels. Despite positive long-term catalysts like the UKidney program, technical indicators suggest continued near-term weakness. Consider re-entering once the stock shows signs of stabilization above the Fibonacci support level of $346.26.

Based on the provided data and market context, here is the price prediction analysis for UTHR stock in 2025:

UTHR is expected to reach $375-385 by end of 2025, driven by strong fundamentals and FDA approval for its UKidney xenotransplantation clinical trial. The company's recent FDA clearance for initiating human trials of gene-edited pig organs positions it as a pioneer in xenotransplantation, which could open up significant new market opportunities.

The stock's technical setup and recent price action suggests a bullish trend continuation pattern forming after consolidating in the $340-350 range.

The S1 support level for UTHR Stock is $345.87 ,The R1 resistant level for UTHR Stock is $371.97.

As of the end of day on 2025-02-12, the price of UTHR Stock was $364.41.

The target price for UTHR Stock according to analyst rating is 407.00, with the highest price target at 460.00 and the lowest at 354.00. Analysts have a Moderate Buy rating on UTHR Stock overall.

The market cap of UTHR is $15.8B.

Based on the latest data, UTHR appears fairly valued with some potential upside. The stock's current P/E ratio of 15.74 and EV/EBITDA of 9.2 in Q3 2024 are reasonable for the biotech sector. Recent FDA clearance for the UKidney xenotransplantation clinical trial represents a significant catalyst for future growth. UBS analyst maintains a Strong Buy rating with a $475 price target, suggesting a 29.57% upside potential from current levels. Heavy insider selling activity with 446 sales and zero purchases in the past six months signals some caution.

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

Based on recent FDA clearance for UKidney xenotransplantation clinical trials and strong institutional investor interest, United Therapeutics (UTHR) stock is projected to reach $520-550 by 2030. The breakthrough in xenotransplantation technology and potential market expansion in organ transplantation could significantly boost revenue growth, though recent insider selling activity suggests some near-term caution. Technical indicators showing RSI at 35.48 and negative MACD suggest current price consolidation, but the long-term growth trajectory remains positive given the company's innovative pipeline and strong market position in rare disease treatments.

UTHR has a total of 1168 employees.